rhodanine and Corneal-Diseases

rhodanine has been researched along with Corneal-Diseases* in 2 studies

Reviews

1 review(s) available for rhodanine and Corneal-Diseases

ArticleYear
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
    Journal of medicinal chemistry, 1985, Volume: 28, Issue:7

    Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; Corneal Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Models, Animal; Fluorenes; Galactose; Humans; Hydantoins; Imidazoles; Imidazolidines; Models, Molecular; Naphthalenes; Phthalazines; Rhodanine; Sorbitol; Structure-Activity Relationship; Substrate Specificity; Sugar Alcohol Dehydrogenases; Thiazolidines; Tissue Distribution

1985

Trials

1 trial(s) available for rhodanine and Corneal-Diseases

ArticleYear
Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study.
    Cornea, 1996, Volume: 15, Issue:4

    The mechanism in the pathogenesis of diabetic corneal disease is unclear, but aldose reductase may be involved in the corneal disease. We studied the effects of an aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients. Fourteen aphakic or pseudophakic patients with diabetes were treated with orally administered ONO-2235 (150 mg/day). Corneal sensation, vital staining of ocular surface, and tear production were examined before and 3 months after the administration. After a 3-month period of oral ARI, corneal sensation recovered significantly (from 4.1 +/- 4.8 to 3.0 +/- 3.1 g/mm2; p = 0.015), with parallel improvements in rose bengal and fluorescein staining scores (p < 0.05). Tear break-up time had also improved (p = 0.003). Results of Schirmer's test (p = 0.03) and the cotton-thread test (p = 0.0001) showed significant improvement in tear production. Improvement in the dynamics of tear production may be due to an improvement in corneal sensitivity. An oral ARI can improve corneal epithelial changes caused by diabetes, probably through recovery of corneal sensation and tear production.

    Topics: Administration, Oral; Aged; Aldehyde Reductase; Cornea; Corneal Diseases; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Rhodanine; Sensation; Tears; Thiazolidines

1996